338 related articles for article (PubMed ID: 21414238)
1. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.
Al-Hamodi Z; Ismail IS; Saif-Ali R; Ahmed KA; Muniandy S
Cardiovasc Diabetol; 2011 Mar; 10():23. PubMed ID: 21414238
[TBL] [Abstract][Full Text] [Related]
2. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
Gürlek A; Bayraktar M; Kirazli S
Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
[TBL] [Abstract][Full Text] [Related]
3. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
4. Effect of plasminogen activator inhibitor-1 and tissue plasminogen activator polymorphisms on susceptibility to type 2 diabetes in Malaysian subjects.
Al-Hamodi Z; Saif-Ali R; Ismail IS; Ahmed KA; Muniandy S
J Biomed Biotechnol; 2012; 2012():234937. PubMed ID: 22577291
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
[TBL] [Abstract][Full Text] [Related]
6. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein(a), tissue plasminogen activator and plasminogen activator inhibitor 1 levels in hyperlipidaemic patients in Kuwait.
Akanji AO; Abdullah A; Tahzeeb S
Eur J Clin Invest; 1997 May; 27(5):380-6. PubMed ID: 9179544
[TBL] [Abstract][Full Text] [Related]
8. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance.
Hadigan C; Meigs JB; Rabe J; D'Agostino RB; Wilson PW; Lipinska I; Tofler GH; Grinspoon SS;
J Clin Endocrinol Metab; 2001 Feb; 86(2):939-43. PubMed ID: 11158071
[TBL] [Abstract][Full Text] [Related]
9. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients.
Vukovich T; Proidl S; Knöbl P; Teufelsbauer H; Schnack C; Schernthaner G
Thromb Haemost; 1992 Sep; 68(3):253-6. PubMed ID: 1440487
[TBL] [Abstract][Full Text] [Related]
10. Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a population-based study.
Hernestål-Boman J; Norberg M; Jansson JH; Eliasson M; Eriksson JW; Lindahl B; Johansson L
Cardiovasc Diabetol; 2012 Dec; 11():152. PubMed ID: 23249721
[TBL] [Abstract][Full Text] [Related]
11. Comparable Enhanced Prothrombogenesis in Simple Central Obesity and Metabolic Syndrome.
Mohd Nor NS; Saimin H; Rahman T; Abdul Razak S; Mohd Nasir N; Ismail Z; Mohd Nawawi H
J Obes; 2018; 2018():8508549. PubMed ID: 29785305
[TBL] [Abstract][Full Text] [Related]
12. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke.
Johansson L; Jansson JH; Boman K; Nilsson TK; Stegmayr B; Hallmans G
Stroke; 2000 Jan; 31(1):26-32. PubMed ID: 10625711
[TBL] [Abstract][Full Text] [Related]
13. The influence of weight loss on fibrinolytic and metabolic parameters in obese children and adolescents.
Sudi KM; Gallistl S; Tröbinger M; Payerl D; Weinhandl G; Muntean W; Aigner R; Borkenstein MH
J Pediatr Endocrinol Metab; 2001 Jan; 14(1):85-94. PubMed ID: 11220710
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity.
Umpaichitra V; Hussain MM; Castells S
Pediatr Res; 2005 Sep; 58(3):483-7. PubMed ID: 15901895
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolysis and diabetic retinopathy in NIDDM.
Mansfield MW; Grant PJ
Diabetes Care; 1995 Dec; 18(12):1577-81. PubMed ID: 8722054
[TBL] [Abstract][Full Text] [Related]
16. Association between Plasma Levels of PAI-1, tPA/PAI-1 Molar Ratio, and Mild Cognitive Impairment in Chinese Patients with Type 2 Diabetes Mellitus.
Wang J; Yuan Y; Cai R; Huang R; Tian S; Lin H; Guo D; Wang S
J Alzheimers Dis; 2018; 63(2):835-845. PubMed ID: 29689724
[TBL] [Abstract][Full Text] [Related]
17. Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study.
Eliasson M; Asplund K; Evrin PE; Lindahl B; Lundblad D
Metabolism; 1994 Dec; 43(12):1579-86. PubMed ID: 7990715
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study.
Tofler GH; Massaro J; O'Donnell CJ; Wilson PWF; Vasan RS; Sutherland PA; Meigs JB; Levy D; D'Agostino RB
Thromb Res; 2016 Apr; 140():30-35. PubMed ID: 26896607
[TBL] [Abstract][Full Text] [Related]
19. Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in diabetic foot syndrome.
Kulwas A; Lisewska B; Jundziłł W; Ruszkowska B; Drewniak W; Ruprecht Z; Gadomska G; Rość D
Adv Med Sci; 2017 Mar; 62(1):87-91. PubMed ID: 28193577
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
